PTC Therapeutics Provides Update to Duchenne Community Following Withdrawal of Ataluren Application

April 1, 2026

On March 31, 2026, PTC Therapeutics, Inc. provided an update to the Duchenne community following the withdrawal of the ataluren (Translarna) approval application in the United States.

To view their letter with updates, please click here.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open